Skip to main content
KANGSTEM BIOTECH CO., LTD. logo

KANGSTEM BIOTECH CO., LTD. — Investor Relations & Filings

Ticker · 217730 ISIN · KR7217730001 KO Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2026-02-03 Director's Dealing
Country KR South Korea
Listing KO 217730

About KANGSTEM BIOTECH CO., LTD.

https://kangstem.com

KANGSTEM BIOTECH CO., LTD. is a biopharmaceutical company that researches and develops advanced stem cell therapies. The company focuses on creating treatments for rare, incurable, and autoimmune diseases, with a pipeline that includes therapeutic candidates for neurological disorders. Leveraging proprietary technologies for the isolation and mass culture of mesenchymal stem cells, Kangstem Biotech also develops and commercializes stem cell culture media and related cosmetic products. The company is dedicated to addressing unmet medical needs through the development of next-generation biopharmaceuticals.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share acquisition (장내매수) by an executive (배요한) of Kangstem Biotech. This is a standard regulatory filing for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2026-02-03 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as a 'Section 6.1' report) used to disclose insider trading activities by company executives. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2026-02-03 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details the share acquisition (장내매수) by an executive (Eo Hae Kwan) of Kangstem Biotech. This type of filing, which reports personal share transactions by company insiders, is classified as 'Director's Dealing'.
2026-02-03 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean regulatory authorities (Financial Supervisory Service/Korea Exchange). It details the share ownership and specific transaction changes (장내매수 - open market purchase) by an executive (Yu Yeon-sil) of Kangstem Biotech. This falls under the category of Director's Dealing (insider trading/ownership reporting).
2026-02-03 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from a Korean company (Kangstem Biotech) announcing a significant change (over 30%) in revenue or profit structure compared to the previous fiscal year. This is a standard mandatory disclosure filing in the Korean market (DART system) regarding financial performance fluctuations. Since it provides the initial financial highlights and reasons for the change before the final audited annual report is published, it falls under the 'Earnings Release' category as it serves as the primary announcement of financial results.
2026-01-23 Korean
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for the purpose of holding an Annual General Meeting (AGM). It is a standard corporate disclosure filed with the regulatory authority to inform shareholders of the upcoming meeting and the associated record date. Since it is a regulatory announcement regarding meeting logistics rather than the meeting materials themselves or a proxy statement, it falls under the general regulatory filing category.
2025-12-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.